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Nucleotide pyrophosphatase/phosphodiesterase type 1 (NPP1) is a membrane
glycoprotein involved in the hydrolysis of extracellular nucleotides. Its major substrate
is ATP which is converted to AMP and diphosphate. NPP1 was proposed as a
new therapeutic target in brain cancer and immuno-oncology. Several NPP1 inhibitors
have been reported to date, most of which were evaluated vs. the artificial substrate
p-nitrophenyl 5′-thymidine monophosphate (p-Nph-5′-TMP). Recently, we observed
large discrepancies in inhibitory potencies for a class of competitive NPP1 inhibitors when
tested vs. the artificial substrate p-Nph-5′-TMP as compared to the natural substrate ATP.
Therefore, the goal of the present study was to investigate whether inhibitors of human
NPP1 generally display substrate-dependent inhibitory potency. Systematic evaluation
of nucleotidic as well as non-nucleotidic NPP1 inhibitors revealed significant differences
in determined Ki values for competitive, but not for non- and un-competitive inhibitors
when tested vs. the frequently used artificial substrate p-Nph-5′-TMP as compared to
ATP. Allosteric modulation of NPP1 by p-Nph-5′-TMP may explain these discrepancies.
Results obtained using the AMP derivative p-nitrophenyl 5′-adenosine monophosphate
(p-Nph-5′-AMP) as an alternative artificial substrate correlated much better with those
employing the natural substrate ATP.
Keywords: ectonucleotidase inhibitors, enzyme assay, p-nitrophenyl 5′-thymidine monophosphate, NPP1, NPP1
inhibitors, nucleotide pyrophosphatase 1
INTRODUCTION
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1; PC-1, EC 3.1.4.1) is an enzyme that
is attached to the cell membrane, or secreted into the extracellular fluid (Zimmermann
et al., 2012). This glycoenzyme is the most important member of the NPP family, which
comprises seven closely related proteins, NPP1–7 (Cimpean et al., 2004). Together with
ecto-nucleoside triphosphate diphosphohydrolases (NTPDases, EC 3.6.1.5), alkaline phosphatases
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(APs, EC. 3.1.3.1) and ecto-5′-nucleotidase (eN, CD73, EC.
3.1.3.5) NPPs regulate extracellular levels of nucleotides by
catalyzing their hydrolysis eventually leading to the formation of
the respective nucleosides and inorganic phosphates (Yegutkin,
2008; Zimmermann et al., 2012). Extracellular nucleosides and
nucleotides play an important role as signaling molecules in
almost all cell tissues and organs by stimulating P1 (adenosine)
and P2 (nucleotide) receptors, respectively. Therefore, ecto-
nucleotidases have recently gained considerable interest as
novel potential drug targets (Sträter, 2006; Kukulski et al.,
2011; Zimmermann et al., 2012; Al-Rashida and Iqbal, 2013).
NPP1 cleaves extracellular nucleoside triphosphates releasing
nucleoside monophosphates and diphosphate (pyrophosphate,
PPi); its main substrate is ATP (see Figure 1). In addition,
it catalyzes the hydrolysis of dinucleotides (e.g. AP4A) and
nucleotide sugars, again releasing nucleoside monophosphates
(e.g., AMP, UMP) along with the remaining part of the molecule
(Zimmermann, 2000; Stefan et al., 2005). cAMP can also be
hydrolyzed to AMP by NPP1 (Jackson and Raghvendra, 2004;
Sassi et al., 2014; Namasivayam et al., 2017). Recently, the cyclic
dinucleotide 2′,3′′-cGAMP has been described to be a substrate
of NPP1 (Li et al., 2014; Namasivayam et al., 2017).
p-Nitrophenyl 5′-thymidinemonophosphate (p-Nph-5′-TMP,
Figure 1) is frequently used as a synthetic substrate for NPP1
to perform kinetic and inhibition assays since the monitoring of
enzymatic reactions using natural substrates is much more time-
consuming and expensive requiring chromatographic separation
or antibodies. The artificial substrate allows colorimetric
monitoring of the enzymatic reaction through the formation of
the intensively yellow-colored p-nitrophenolate, which absorbs
at 400 nm (Henz et al., 2007; Buffon et al., 2010). The use of this
artificial substrate is popular since it is straightforward and allows
high-throughput screening of compound libraries.
NPP1 has been implicated in various physiological and
pathological processes. Together with tissue non-specific alkaline
phosphatase (TNAP) NPP1 plays an important role in the
regulation of bone mineralization and soft-tissue calcification by
generating diphosphate (pyrophosphate, PPi; Terkeltaub, 2006;
Mackenzie et al., 2012). Furthermore, independent of its catalytic
activity, NPP1 was reported to downregulate insulin signaling
by reducing tyrosine kinase activity of insulin receptors (Abate
et al., 2006; Goldfine et al., 2008). NPP1 expression has been
reported to be increased in membranes of rat C6 glioma cells
(Grobben et al., 2002), human astrocytic brain tumors (Aerts
et al., 2011), and human glioblastoma stem-like cells (Bageritz
et al., 2014). Increase in NPP1 expression was found to correlate
with the aggressiveness of astrocytic brain tumors (Aerts et al.,
Abbreviations: α,β-metADP, adenosine 5′-(α,β-methylene)diphosphate; α,β-
metATP, adenosine 5′-(α,β-methylene)triphosphate; CE, capillary electrophoresis;
CHES, 2-(N-cyclohexylamino)-ethanesulfonic acid; dialADP, adenosine
5′-diphosphate-2′,3′-dialdehyde; dialATP, adenosine 5′-triphosphate-2′,3′-
dialdehyde; 2-MeSADP, 2-methylthioadenosine 5′-diphosphate; 2-MeSATP, 2-
methylthioadenosine 5′-triphosphate; p-Nph-5′-AMP, p-nitrophenyl 5′-adenosine
monophosphate; p-Nph-5′-TMP, p-nitrophenyl 5′-thymidine monophosphate;
NPP, nucleotide pyrophosphatase/phosphodiesterase; PZB08513136A, 2-(6-
amino-9H-purin-8-ylthio)-N-(3,4-dimethoxyphenyl)acetamide; SAR 03004,
N-[2-[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]ethyl]sulfuric diamide.
2011). NPP1 has also been reported to be expressed in N2amouse
neuroblastoma cells, and its expression level was reduced when
the cells differentiated into a neuronal-like phenotype (Gómez-
Villafuertes et al., 2014). Thus, NPP1 inhibitors might be useful
for the treatment of brain cancers. The main substrate of NPP1,
ATP, is a proinflammatory signaling molecule. Its concentration
is increased in the tumor microenvironment by damaged or
dying cells (Antonioli et al., 2013). Along with CD73 NPP1
can convert ATP via AMP to the immunosuppressive signaling
molecule adenosine (Horenstein et al., 2013), which is a critical
regulator of both innate and adaptive immune responses by
stimulating Gs protein-coupled A2A and A2B adenosine receptors
(Gessi et al., 2007; Bastid et al., 2013). Extracellular adenosine
inhibits macrophages and neutrophils, T- and B-cell triggered
NF-kB activation, and the production of a series of cytokines
such as interleukin-2 (IL-2), interleukin-4 (IL-4), or interferon-
gamma (INF-γ) in diverse immune cells (e.g., mast cells, natural
killer T cells, dendritic cells, and T lymphocytes; Colgan et al.,
2006; Gessi et al., 2007; Stagg and Smyth, 2010; Bergamin et al.,
2012; Ghiringhelli et al., 2012; Bastid et al., 2013). Additionally,
extracellular adenosine facilitates the differentiation of native T
cells into regulatory T cells (Treg cells), which leads to a drastically
impaired antitumor immune response (Stagg and Smyth, 2010;
Bastid et al., 2013). The inhibition of NPP1 may reduce
the formation of extracellular adenosine by diminishing the
concentration of extracellular AMP. At the same time it prevents
the hydrolysis of ATP, which may directly promote phagocytosis
and immunogenicity of the immune cells by stimulating certain
P2 receptors (Burnstock and Di Virgilio, 2013; Burnstock and
Boeynaems, 2014). Moreover, the blockade of NPP1 may lead to
an increase in the concentration of 2′,3′′-cGAMP, the agonist of
STING, resulting in an increased formation of type 1 interferons
(Barber, 2014; Li et al., 2014; Woo et al., 2015). Thus, NPP1
inhibitors hold high potential for the immunotherapy of cancer.
Several small molecule NPP1 inhibitors have been
described in the literature. One class of inhibitors is
derived from the natural substrates and represents
adenine nucleotide derivatives or analogs (see Figure 2).
Adenosine 5′-diphosphate-2′,3′-dialdehyde (dialADP, 1),
adenosine 5′-triphosphate-2′,3′-dialdehyde (dialATP, 2),
adenosine 5′-(α,β-methylene)diphosphate (α,β-metADP, 3),
adenosine 5′-(α,β-methylene)triphosphate (α,β-metATP, 4),
2-methylthio-adenosine 5′-diphosphate (2-MeSADP, 5), 2-
methylthio-adenosine 5′-triphosphate (2-MeSATP, 6), and 2′
(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate (bzATP, 7)
were described as inhibitors of human NPP1 with Ki-values in
the range of 5–27 µM, determined vs. the natural substrate ATP
(Lee and Müller, 2014). Furthermore, the standard NTPDase1
inhibitor N6,N6-diethyl-β,γ-dibromomethylene-ATP (ARL
67156, 8) was reported to be a weak inhibitor of human NPP1
with a Ki-value of 12 µM when tested vs. p-Nph-5′-TMP as a
substrate (Lévesque et al., 2007). A series of diadenosine 5′,5′′-
P1,P5-α,β-methylene-δ,ε-methylene-γ-boranopentaphosphates,
tested in an assay employing p-Nph-5′-TMP as a substrate
and recombinantly NPP1-expressing membrane preparations
of COS-7 cells as the enzyme source, showed similarly high
inhibitory potency at human NPP1, the most potent inhibitor,
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FIGURE 1 | Hydrolysis of the natural substrate ATP (A) and the artificial substrate p-Nph-5′-TMP (B) by NPP1.
FIGURE 2 | NPP1 inhibitors with nucleotide structure derived from natural substrates.
compound 9 (Figure 2), displaying a Ki-value of 9 µM (Eliahu
et al., 2010). Subsequently, a new series of metabolically stable
ATP analogs, β,γ-methylene-ATP derivatives bearing an α-
borano group (e.g., 10, Figure 2), was developed and optimized
as NPP1 inhibitors. They were tested vs. p-Nph-5′-TMP as a
substrate, and the best compound displayed a Ki-value of 0.5 µM
(Lecka et al., 2013). Recently, a new series of α,β-methylene-ATP
derivatives was investigated, and potent inhibitors for human
NPP1, determined vs. p-Nph-5′-TMP, were developed, the
most potent one being adenosine 5′-γ-thio-α,β-methylene
triphosphate (11) which showed a Ki-value of 0.02 µM (Nadel
et al., 2014). The nucleotide derivatives and analogs were shown
to display a competitive mechanism of NPP1 inhibition (Laketa
et al., 2010; Lecka et al., 2013; Lee and Müller, 2014). Only
the dialdehyde derivatives obtained by oxidation of adenine
nucleotides, i.e., dialADP (1) and dialATP (2), were reported to
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inhibit NPP1 in a non-competitive (1) or uncompetitive manner
(2) (Lee and Müller, 2014).
Non-nucleotide-derived NPP1 inhibitors have also been
described (see Figure 3). A series of quinazoline-4-piperidine-4-
methylsulfamides was reported as potent NPP1 inhibitors tested
against ATP as a substrate, the most potent derivative being SAR
03004 (12) with an IC50-value of 0.036 µM (Patel et al., 2009).
The mechanism of inhibition was not determined in that study.
Very recently, 12 was further investigated as an NPP1 inhibitor
using a colorimetric assay with p-Nph-5′-TMP as a substrate.
The study confirmed that the quinazoline derivative possesses
high inhibitory potency with a Ki-value of 0.059 µM (Shayhidin
et al., 2015). However, that class of compounds also showed high
affinity binding to hERG potassium channels, which precluded
its further development as a drug, since QT prolongation was to
be expected as a side-effect (Patel et al., 2009; Shayhidin et al.,
2015). The non-selective purine P2 receptor antagonists reactive
blue 2 (13) and suramin (14) were reported to be relatively potent
NPP1 inhibitors vs. ATP as a substrate, displaying Ki-values
of 0.52 and 0.26 µM, respectively (Iqbal et al., 2008). Their
mechanism of inhibition has not been reported. Recently, a
series of thioacetamide derivatives was developed as potent
competitive NPP1 inhibitors vs. p-Nph-5′-TMP as a substrate,
the most potent derivative PZB08513136A (15) displaying a Ki-
value of 0.00500 µM (Chang et al., 2014). Moreover, inorganic
polyoxometalates, e.g., [TiW11CoO40]8− (PSB-POM141, 16),
were discovered to be potent and selective non-competitive NPP1
inhibitors, the best compound showing a Ki-value of 0.00146µM
vs. ATP as a substrate. This compound represents themost potent
inhibitor of human NPP1 described to date (Lee et al., 2015).
The majority of reported NPP1 inhibitors has only been
investigated under completely unnatural conditions using
spectrophotometric assays with p-Nph-5′-TMP as an artificial
substrate. However, in several studies substrate-dependent
inhibitory potencies of various competitive enzyme inhibitors
had been observed (Michaud et al., 1997; Hosoda et al.,
1999; Schiemann et al., 2012; Ben Henda et al., 2013; Chang
et al., 2014; Lee and Müller, 2014). For example, captopril, a
competitive inhibitor of angiotensin-I converting enzyme (ACE),
was significantly more potent when the synthetic substrates N-
[3-(2-furyl)acryloyl]-Phe-Gly-Gly (FAPGG) or N-hippuryl-His-
Leu hydrate (HHL) were used instead of the natural substrate
angiotensin-I (Michaud et al., 1997; Ben Henda et al., 2013).
Such a discrepancy in inhibitory potencies depending on the
substrate was also observed for NPP2 (autotaxin) (Schiemann
et al., 2012), an enzyme that is closely related to NPP1 but
prefers phospholipids rather than nucleotides as substrates (Aoki
et al., 2008). In our laboratory, we recently found that the
inhibitory potencies of several nucleotidic inhibitors of NPP1
were significantly lower when tested vs. ATP as compared
to the commonly used artificial substrate p-Nph-5′-TMP (Lee
and Müller, 2014). The non-nucleotide-derived thioacetamides
(e.g., compound 15, Figure 3) displayed a particularly large
discrepancy being much more potent vs. p-Nph-5′-TMP as a
substrate than vs. ATP (more than 100-fold difference for 15)
(Chang et al., 2014). Thus, the goal of the present study was (i) to
fundamentally investigate whether substrate-dependent potency
of NPP1 inhibitors was a common phenomenon, and (ii) to
find a possible explanation for these observations. To this end,
we evaluated a wide range of structurally and mechanistically
diverse NPP1 inhibitors vs. both, the artificial substrate p-
Nph-5′-TMP and the natural substrate ATP, considering
both, nucleotidic and non-nucleotidic structures. The results
were compared and correlation coefficients were calculated.
Moreover, we synthesized and evaluated a new artificial substrate,
p-nitrophenyl 5′-adenosine monophosphate (p-Nph-5′-AMP),
which is structurally more similar to ATP than the standard
artificial substrate. The results of this study will be highly relevant
FIGURE 3 | Potent, non-nucleotide-derived NPP1 inhibitors.
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with respect to in vivo studies with NPP1 inhibitors and for
translational research aimed at drug development.
MATERIALS AND METHODS
Materials
Adenosine 5′-(α,β-methylene)diphosphate (α,β-metADP),
adenosine 5′-(α,β-methylene)triphosphate (α,β-metATP),
adenosine 5′-diphosphate-2′,3′-dialdehyde (dialADP),
adenosine 5′-monophosphate (AMP), adenosine 5′-triphosphate
(ATP), adenosine 5′-triphosphate-2′,3′-dialdehyde (dialATP),
2-methylthioadenosine 5′-diphosphate (2-MeSADP),
2-methylthioadenosine 5′-triphosphate (2-MeSATP), p-
nitrophenol, p-nitrophenyl 5′-thymidine monophosphate
(p-Nph-5′-TMP), reactive blue 2, suramin, and uridine 5′-
triphosphate (UTP) were obtained from Sigma (Steinheim,
Germany). Calcium chloride, magnesium chloride, sodium
hydroxide, and zinc chloride were also from Sigma.
2-(N-Cyclohexylamino)ethanesulfonic acid (CHES) and tris-
(hydroxymethyl)aminomethane (Tris) were from Applichem
(Darmstadt, Germany). Disodium hydrogen phosphate was
purchased from Carl Roth (Karlsruhe, Germany). 2-(6-
Amino-9H-purin-8-ylthio)-N-(3,4-dimethoxyphenyl)acetamide
(PZB08513136A) was synthesized and provided by the group
of Prof. Dr. Piet Herdewijn as previously described (Chang
et al., 2014). N-[2-[1-(6,7-Dimethoxyquinazolin-4-yl)piperidin-
4-yl]ethyl]sulfuric diamide (SAR 03004) was synthesized
as described in Supporting Information. [TiW11CoO40]8−
(PSB-POM141) (Müller et al., 2006) was provided by Dr.
Holger Stephan (Institute of Radiopharmaceutical Cancer
Research, Helmholtz-Zentrum Dresden—Rossendorf). Human
recombinant soluble NPP1 (Val191—Leu591) expressed in
murine myeloma NS0 cells was purchased from R&D Systems
GmbH (Wiesbaden, Germany, purity > 95%, purified by using
N-terminal His-tag).
Synthesis of p-Nitrophenyl 5′-Adenosine
Monophosphate
p-Nitrophenyl 5′-adenosine monophosphate (p-Nph-5′-AMP)
was synthesized in analogy to a described procedure (Borden
and Smith, 1966; Ivanovskaya et al., 1987). Adenosine-5′-
monophosphate disodium salt (17, see Figure 4, 1.0 g) was
dissolved in 20 mL of deionized water. To this solution was
added Dowex 50X8 proton form (2 gram) prewashed three times,
each with 100 mL of deionized water. The resulting adenosine-
5′-monophosphoric acid (18, see Figure 4) was separated by
filtration and freeze-dried. Adenosine-5′-monophosphoric acid
(18, 347 mg) was dissolved in pyridine (10 mL) containing
triethylamine (1.4 mL). To this was added p-nitrophenol (1.4 g)
followed by dicyclohexylcarbodiimide (2.0 g), and the mixture
was stirred in the dark for 3 days at room temperature, until
complete disappearance of adenosine-5′-monophosphosphoric
acid as indicated by thin layer chromotagraphy (TLC, solvent
system: n-butanol: acetic acid: water = 2:1:1). Pyridine was
subsequently removed under reduced pressure, the residue was
suspended in water (100mL), and insoluble dicyclohexylurea was
removed by filtration. The aqueous layer was washed three times
with diethyl ether (3 × 50 mL) to remove excess p-nitrophenol,
and the aqueous layer was freeze-dried. Then the freeze-dried
crude product was subjected to C-18 reverse phase-HPLC using
a gradient of acetonitrile: 50 mM aqueous NH4HCO3 solution
from 0:100 to 25:75 for 50 min. Appropriate fractions were
pooled and freeze-dried several times to obtain dry p-nitrophenyl
5′-adenosine monophosphate (19 in Figure 4) as a white solid;
yield: 62%. The final product was characterized by LC-MS, 1H,
13C, and 31P NMR spectroscopy. 1H NMR (500 MHz, MeOD-
d4): δ 4.23–4.26 (1H, q, H4′, J = 5.70 Hz), 4.29–4.36 (2H, m,
H5′and H5′′CH2, J = 4.40 Hz), 4.41–4.43 (1H, q, H3′, J = 5.05
Hz), 4.70–4.72 (1H, t, H2′, J′ = 5.03 Hz and J′′ = 5.35 Hz), 6.11–
6.12 (1H, d, H1′, J = 5.35 Hz), 7.38–7.40 (2H, d, Ph-CH2, J =
9.15 Hz), 8.10–8.12 (2H, d, Ph-CH2, J = 9.45 Hz), 8.33 (1H, s,
H2), 8.56 (1H, s, H8). 13C NMR (125 MHz, MeOD-d4): δ 67.05,
72.30, 76.34, 86.00, 89.85, 120.36, 121.97, 126.45, 143.36, 144.88,
147.92, 150.57, 152.41, 159.91. 31P NMR (202 MHz, MeOD-d4)
δ –6.47 (s). LC-ESI-MS: negative mode 467 ([M – H]−), positive
mode 469 ([M+H]+).
Determination of Kinetic Parameters of
Artificial Substrates
Enzyme kinetic parameters were measured for p-Nph-5′-TMP
and p-Nph-5′-AMP, both being artificial substrates of human
NPP1. Solutions with different concentrations of both substrates
(ranging from 1.0 to 500 µM) were prepared in 10 mM CHES
buffer (in mM: 1 MgCl2, 2 CaCl2, 10 CHES, pH 9.0) and
added in a final volume of 100 µl to 96-well-plates. The enzyme
reactions were initiated by the addition of 20 ng of human
NPP1 (for p-Nph-5′-TMP), or 75 ng of human NPP1 (for p-
Nph-5′-AMP). The mixture was incubated at 37◦C for 15 min
(p-Nph-5′-TMP), or 30 min (for p-Nph-5′-AMP), respectively,
FIGURE 4 | Synthesis of p-nitrophenyl 5 ′-adenosine monophosphate. Reagents and conditions were as follows: (a) Dowex 50x8 protonated form, 1h; (b) (i)
p-nitrophenol, dicyclohexylcarbodiimide, triethylamine, pyridine, room temperature, 3 days in the dark; (ii) C-18 RP-HPLC, gradient of acetonitrile: 50 mM aqueous
NH4HCO3 = 0:100–25:75.
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and subsequently terminated by the addition of 20 µl of 1.0N
aqueous NaOH solution. The amounts of p-nitrophenolate
liberated were measured at 400 nm. Each analysis was repeated
twice in three separate experiments.
Determination of
Concentration-Dependent Inhibition
Curves
Concentration-response curves of NPP1 inhibition were
determined for six nucleotidic inhibitors [dialADP (1),
dialATP (2), α,β-metADP (3), α,β-metATP (4), 2-MeSADP
(5), and 2-MeSATP (6), see Figure 2] and five non-nucleotidic
inhibitors [SAR 03004 (12), reactive blue 2 (13), suramin (14),
PZB08513136A (15), and [TiW11CoO40]8− (16), see Figure 3],
and with different substrates. For testing vs. both synthetic
substrates, p-Nph-5′-TMP and p-Nph-5′-AMP, solutions
containing different concentrations of each inhibitor were
prepared with 10mMCHES buffer (See SectionDetermination of
Kinetic Parameters of Artificial Substrates) containing 400µM p-
Nph-5′-TMP, or p-Nph-5′-AMP, respectively, in a final volume of
100 µl. Incubation and operation conditions remained the same
as described in Section Determination of Kinetic Parameters of
Artificial Substrates, with one exception: reactive blue 2 absorbs
light at 400 nm. Therefore, measurements were not performed
colorimetrically, but by capillary electrophoresis (CE) with
DAD detection of the formed p-nitrophenolate at 400 nm. The
CE instrumentation and operation conditions were as follows:
The CE instrumentation and operating conditions were as
follows: P/ACEMDQ capillary electrophoresis system (Beckman
Instruments, Fullerton, CA, USA) with a DAD detection system,
polyacrylamide-coated capillaries of 50 cm effective length
× 50 µm (id) obtained from CS Chromatographie GmbH
(Langerwehe, Germany), 100 mM phosphate buffer (pH 6.5) as
running buffer, electrokinetic injection (−6 kV, 60 s), separation
voltage of −20 kV. The measurement was performed twice
in three different experiments. Data collection and peak area
analysis were performed by the 32 Karat software obtained from
Beckman Coulter (Fullerton, CA, USA). The IC50-values of test
compounds for each substrate were calculated by plotting of
three independent experiments using the program Prism 5.0
(GraphPad software, San Diego, CA, USA).
For the natural substrate ATP, the enzyme inhibition assays
were performed in 10 mM CHES buffer containing 400
µM of substrate along with different inhibitor concentrations.
Incubation and operation conditions were the same as described
above with artificial substrates. The analysis was performed by CE
and the amounts of AMP produced were quantified by their UV
absorption at 260 nm. Each analysis was repeated twice in three
separate experiments.
Determination of Inhibition Constants and
Mechanism of Inhibition
The inhibition mechanisms of the nucleotidic and non-
nucleotidic inhibitors were determined using different
concentrations of each substrate (from 10 to 1500 µM),
and three different concentrations (0, ∼0.5- and ∼2-fold of
IC50-value) of each test compound. The instrumentations and
operation conditions for the experiments were the same as those
described in the Sections Determination of Kinetic Parameters
of Artificial Substrates and Determination of Concentration-
Dependent Inhibition Curves. Each analysis was performed in
three separate experiments. The inhibition type of each inhibitor
was then evaluated graphically from the Hanes-Woolf plots. For
the determination of the (α)Ki-values the slope of the reciprocal
lines from the Hanes-Woolf plot were plotted as a function of
inhibitor concentrations using Prism 5.0.
Molecular Docking of Artificial Substrates
The generated homology model of human NPP1 described in
Namasivayam et al. (2017). was used for the docking procedure
using AutoDock 4.2 (Morris et al., 2009). The AutoDockTools
package was employed to generate the docking input files
and to analyze the docking results (Sanner, 1999). The search
algorithm Lamarkian genetic algorithm (LGA) and the default
scoring function, a hybrid scoring function (semi-empirical
and free-energy) was employed for docking calculations. Three-
dimensional energy scoring grids for a box of 60 × 60 × 60
points with a spacing of 0.375 Å were computed. The grids
were centered based on the co-crystallized ligand, which was
transformed into the homology model. A total of 50 runs with
a maximum of 250,000 energy evaluations were performed with
the default parameters for the genetic algorithm (GA) and Solis-
Wet local search, a method that facilitates random moving
around the binding pose identified through the GA. High scoring
binding poses (of lowest energy) or more populated poses were
selected for the analysis on the basis of visual inspection.
Statistical Analyses
Statistical data analyses of pKi-values were performed using
Prism 5.0 software. The pKi-values [–log10(α)Ki-values] were
calculated from the obtained (α)Ki-values in each assay. Data
were tested for statistical significance by one-way ANOVA as
appropriate. When significant differences were observed, Tukey
multiple comparison tests were performed. A value of p < 0.05
was considered significant.
Calculation of Correlation Coefficients
between Assays with Different Substrates
The correlation coefficients (R2) were evaluated by comparing
pKi-values of one assay to those of another assay using Prism 5.0.
RESULTS AND DISCUSSION
The main natural substrate of NPP1, ATP (Figure 1A), and
the generally used artificial NPP1 substrate, p-Nph-5′-TMP
(Figure 1B; Laketa et al., 2010; Lee et al., 2012), differ not only
in the phosphoric ester part (triphosphate vs. p-nitrophenyl
phosphate), but also with respect to their nucleoside partial
structure (adenosine vs. thymidine). In order to investigate
potential substrate-dependence of various NPP1 inhibitors, we
intended to test selected antagonists vs. both substrates. But, in
addition, we decided to additionally evaluate them on a second
artificial substrate, which is structurally more closely related
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to ATP, namely p-nitrophenyl 5′-adenosine monophosphate (p-
Nph-5′-AMP, 19). Since 19 was not commercially available we
decided to synthesize the compound.
Synthesis of a New Artificial Substrate of
NPP1
p-Nph-5′-AMP had been previously synthesized (Borden and
Smith, 1966; Ivanovskaya et al., 1987), but no detailed
characterization of the compound has been published. Initially
we tried to prepare 19 directly from adenosine by reaction
with p-nitrophenyl phosphorodichloridate. However, the reagent
is toxic and difficult to handle. Moreover, tedious separation
and purification procedures were required to obtain the desired
product in sufficient purity, and the yield was only about 20%.
Therefore, we decided to utilize commercially available AMP
(17) for the preparation of 19. In a one-step reaction AMP
was condensed with p-nitrophenol in the presence of N,N′-
dicyclohexylcarbodiimide yielding product 19 in 62% yield after
purification (see Figure 4).
Biochemical Characterization and
Molecular Docking of the New Artificial
Substrate
In subsequent experiments, we characterized the newly
synthesized alternative substrate p-Nph-5′-AMP in comparison
with the common artificial substrate p-Nph-5′-TMP and the
natural substrate ATP. Enzyme kinetic analysis showed the
following rank order of substrate preference: ATP > > p-Nph-
5′-TMP > p-Nph-5′-AMP. The kcat/Km-values are 674 × 103
M−1s−1 (kcat = 5.51 s−1, Km = 8.17µM) for ATP (Namasivayam
et al., 2017), 100 × 103 M−1s−1 (kcat = 22.3 s−1, Km = 222 µM)
for p-Nph-5′-TMP (Namasivayam et al., 2017), and 13.4 × 103
M−1s−1 (kcat = 2.51 s−1, Km = 188 µM) for p-Nph-5′-AMP
(see Figure S1 in Supporting Information). While the Km-value
of p-Nph-5′-AMP was almost identical to that of p-Nph-5′-TMP
indicating similar affinities, the kcat-value determined for p-Nph-
5′-TMP was nearly 10-fold higher than that for p-Nph-5′-AMP.
This means that p-Nph-5′-TMP is hydrolyzed by NPP1 much
faster than p-Nph-5′-AMP. Compared to the natural substrate
ATP, the new artificial substrate has a similar kcat-value, but its
Km-value is > 20-fold higher than that for ATP. This indicates
that the binding affinity of p-Nph-5′-AMP is significantly lower
than that of ATP.
In order to gain insights into the molecular determinants
involved in the formation of the enzyme-substrate complex,
the new artificial substrate p-Nph-5′-AMP was docked into
a homology model of the human NPP1 (Namasivayam et al.,
2017), which was generated based on the recently solved crystal
structure of the mouse NPP1 (Kato et al., 2012). The observed
interactions were compared to those of ATP and p-Nph-5′-TMP.
As shown in Figure 5A, the α-phosphate group of the substrate
ATP is bound between the two zinc ions, and the two other
phosphate groups form hydrogen bond interactions with the
following amino acid residues: Lys255, Thr256, Asn277, His380,
and His535. Tyr340 forms a hydrogen bond with the ribose
moiety, and the adenine ring of ATP is stacked between Phe257
and Tyr340 (Namasivayam et al., 2017). Similarly, both artificial
substrates form complexes with the zinc ions of the enzyme
with their phosphate groups as shown in Figures 5B,C. Because
the p-nitrophenylphosphate group of both artificial substrates
interacts in the same way with the zinc ions in the active site
of the enzyme, the ground state of binding interactions may be
comparable, which explains the similar Km-values determined
for both artificial substrates. While p-Nph-5′-AMP binding is
stabilized through pi-pi interactions of the adenine base mainly
with Tyr340 of the enzyme, this interaction is expected to be
weaker for the artificial substrate p-Nph-5′-TMP due to the
exchange of adenine for thymine. Furthermore, a 2′-hydroxyl
group at the ribose moiety is lacking in p-Nph-5′-TMP, but
not in p-Nph-5′-AMP, and therefore, the interaction between
that OH group and the side chain of Tyr340 is missing in p-
Nph-5′-TMP. Overall, p-Nph-5′-TMP has less interactions than
p-Nph-5′-AMP and therefore, it may be hydrolyzed faster via the
transition state than the new artificial substrate. This may explain
why p-Nph-5′-TMP showed a significantly higher kcat-value than
p-Nph-5′-AMP.
Characterization of NPP1 Inhibitors vs.
Different Substrates
Several previous studies had indicated that the potency of
enzyme inhibitors may be dependent on the substrate used for
FIGURE 5 | Putative binding modes of NPP1 substrates. Docking poses of (A) ATP (cyan colored), (B) the commonly used artificial substrate p-Nph-5′-TMP
(green), and (C) the new artificial substrate p-Nph-5′-AMP (yellow) represented as sticks. Important residues in the binding pocket are shown (white); oxygen atoms
are colored in red, nitrogen atoms in blue, and phosphorus atoms in orange. The zinc ions in the active site are represented as spheres (marine blue).
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FIGURE 6 | Concentration-dependent inhibition curves for non-nucleotidic and nucleotidic inhibitors vs. different substrates (A: ATP, B: p-Nph-5′-TMP,
C: p-Nph-5′-AMP). Figures represent means ± SD from three independent experiments.
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testing (Michaud et al., 1997; Hosoda et al., 1999; Schiemann
et al., 2012; Ben Henda et al., 2013; Chang et al., 2014;
Lee and Müller, 2014). Therefore, we decided to investigate
a selection of standard NPP1 inhibitors vs. three different
substrates: six nucleotidic inhibitors, dialADP (1), dialATP
(2), α,β-metADP (3), α,β-metATP (4), 2-MeSADP (5) and 2-
MeSATP (6), and five non-nucleotidic inhibitors, SAR 03004
(12), reactive blue 2 (13), suramin (14), PZB08513136A (15),
and [TiW11CoO40]8− (16) (for structures see Figures 2, 3). The
concentration-inhibition curves of the test compounds vs. the
natural substrate ATP and the two artificial substrates p-Nph-
5′-TMP and p-Nph-5′-AMP are presented in Figure 6. Table 1
displays the (α)Ki-values and the determined inhibition types of
the NPP1 inhibitors. Six of the investigated inhibitors displayed a
competitive mechanism of NPP1 inhibition (also see Figure S2 in
Supporting Information). As expected, this was independent of
the structure of the substrate and could be confirmed for all three
investigated substrates. [TiW11CoO40]8−, reactive blue 2 and
dialADP inhibited the enzymatic activity in a non-competitive
manner, while suramin and dialATP were characterized as un-
competitive inhibitors vs. all investigated substrates. Differences
in inhibitory potential with respect to structure of inhibitor
also exist. Among the investigated competitive inhibitors, the
quinazoline sulfonamide derivative SAR 03004 (12) was found
to be the most potent compound vs. ATP and also vs. p-Nph-
5′-AMP with Ki-values of 0.215 and 0.420 µM, respectively. To
the contrary, when p-Nph-5′-TMP was employed as a substrate,
the thioacetamide derivative PZB08513136A (15) was found to
be the most potent competitive inhibitor with a Ki-value of
0.00500µM.Among the investigated non-competitive inhibitors,
[TiW11CoO40]8− (16) was the most potent compound vs. all
investigated substrates (Ki-values: 0.00146 µM vs. ATP, 0.00199
µM vs. p-Nph-5′-TMP and 0.00174 µM vs. p-Nph-5′-AMP). In
the group of un-competitive inhibitors, suramin (14) was found
to be the most potent compound vs. all investigated substrates
(Ki-values: 0.780 µM vs. ATP, 1.07 µM vs. p-Nph-5′-TMP and
1.03 µM vs. p-Nph-5′-AMP). Among the adenosine analogs
and derivatives, the two dialdehyde compounds (dialADP;
non-competitive inhibitor, dialATP; un-competitive inhibitor)
displayed NPP1-inhibitory activities with Ki-values around 5
µM vs. all substrates. The other investigated adenine nucleotide
derivatives and analogs were mostly less active vs. the three
different substrates (Ki-values: 13.0–32.8 µM vs. ATP, 1.28–
4.47 µM vs. p-Nph-5′-TMP and 8.19–39.9 µM vs. p-Nph-5′-
AMP).
Correlation
Inhibitory potencies of non-nucleotidic and nucleotidic
inhibitors vs. different substrates were compared (Figure 7).
Data analysis revealed substrate-dependent inhibitory potencies
of competitive inhibitors, but not of non- or uncompetitive
inhibitors. When Ki-values obtained with the natural substrate
ATP were compared with those obtained with the artificial
substrate p-Nph-5′-TMP the competitive inhibitors were 3–
3600-fold more potent against p-Nph-5′-TMP than vs. ATP
[p < 0.05 for SAR 03004 (12), p < 0.01 for α,β-metATP (4)
and 2-MeSATP (6), and p < 0.001 for α,β-metADP (3), 2-
MeSADP (5) and PZB08513136A (15)]. Differences were also
dependent on the structure of the competitive antagonists,
e.g., it was particularly high for the thioacetamide derivative
PZB08513136A (15), but less pronounced for the quinazoline
derivative SAR 03004 (12). In contrast, results obtained vs.
the new artificial substrate p-Nph-5′-AMP were similar to
those obtained vs. the natural substrate ATP. As opposed to
competitive inhibitors, substrate-dependent inhibition was not
observed for non-competitive and un-competitive inhibitors,
TABLE 1 | (α)Ki-values and inhibition types of nucleotidic and non-nucleotidic inhibitors of human NPP1 using different substrates.
Inhibitors Ki ± SD (µM)
a Inhibition type
ATP p-Nph-5′-TMP p-Nph-5′-AMP
NUCLEOTIDIC INHIBITORS
dialADP (1) 5.62 ± 1.23 5.03 ± 0.15 5.09 ± 1.72 Non-competitive
dialATP(2) 6.82 ± 1.01b 4.09 ± 0.41b 5.08 ± 0.33b Un-competitive
α,β-metADP (3) 16.5 ± 3.1 1.28 ± 0.16 25.8 ± 4.1 Competitive
α,β-metATP (4) 13.0 ± 3.0 3.32 ± 0.51 8.19 ± 1.32 Competitive
2-MeSADP (5) 32.8 ± 7.0 2.18 ± 0.29 35.4 ± 6.4 Competitive
2-MeSATP (6) 25.3 ± 5.9 4.47 ± 0.66 39.9 ± 6.9 Competitive
NON-NUCLEOTIDIC INHIBITORS
SAR 03004 (12) 0.215 ± 0.099 0.0642 ± 0.0192 0.420 ± 0.090 Competitive
Reactive blue 2 (13) 0.141 ± 0.031 0.198 ± 0.034 0.176 ± 0.025 Non-competitive
suramin (14) 0.780 ± 0.081b 1.07 ± 0.23b 1.03 ± 0.22b Un-competitive
PZB08513136A (15) 18.0 ± 2.7c 0.00500 ± 0.00077c 14.9 ± 0.8 Competitive
[TiW11CoO40]
8− (16) 0.00146 ± 0.00001d 0.00199 ± 0.00033 0.00174 ± 0.00099 Non-competitive
aResults are expressed as means (in bold) ± SD of three independent experiments.
bαKi-value.
cKi-values from the literature (Chang et al., 2014), expressed as means ± SEM.
dKi-values from the literature (Lee et al., 2015), expressed as means ± SEM.
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FIGURE 7 | Continued
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FIGURE 7 | Comparison of inhibitory potency of nucleotidic (A) and non-nucleotidic (B) inhibitors using different substrates. Data are means ± SDs of
pKi-values. The bars in gray represent pKi-values of inhibitors vs. the natural substrate ATP, those in red are the pKi-values of inhibitors vs. p-Nph-5
′-TMP and those
in blue are pKi values vs. p-Nph-5
′-AMP. *p < 0.05, **p < 0.01, and ***p < 0.001.
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and very similar inhibition constants were obtained vs. all
investigated substrates.
Correlation analyses of pKi-values obtained vs. one substrate
with those measured vs. another substrate were performed.
Considering the competitive inhibitors, a low correlation
of data obtained with p-Nph-5′-TMP as a substrate with
those obtained with the natural substrate ATP was obtained
[correlation coefficient (R2) = 0.5722, see Figure 8A], whereas
a high correlation between the results obtained with p-
Nph-5′-AMP as a substrate and those determined with ATP
was observed (R2 = 0.9578). Moreover, Figure 8A (left)
showed that the data points were shifted to the right of the
ideal correlation line [dotted line in Figure 8A (left)]. This
indicates that the competitive NPP1 inhibitors were generally
more potent vs. p-Nph-5′-TMP than vs. ATP as a substrate.
Contrary to this, the non- and un-competitive inhibitors
showed high correlations, no matter which substrates were
used for comparison (R2 = 0.9742 for competitive inhibitors;
R2 = 0.9900 for non- and un-competitive inhibitors), see
Figure 8B.
Possible Explanation for
Substrate-Dependence of Competitive
NPP1 Inhibitors
The observation of significantly different potencies of
competitive enzyme inhibitors when determined vs. different
substrates is puzzling, and an explanation for this phenomenon
is not straightforward. The different assay conditions are clearly
not the reason for the observed discrepancies because the same
operating conditions (e.g., same stock solutions of inhibitors,
same assay buffer) were applied for the enzyme inhibition
assays with different substrates. A rational explanation for
the different results between assays obtained with p-Nph-5′-
TMP and the natural substrate ATP could be an allosteric
modulatory effect by p-Nph-5′-TMP on the enzyme, in
addition to acting as a substrate (Figure 9). Such allosteric
binding of the substrate has previously been reported for
another nucleotide-metabolizing enzyme, bacterial UDP-N-
acetylglucosamine 2-epimerase, which is allosterically modulated
by its substrate UDP-N-acetylglucosamine (Velloso et al.,
2008). The binding of p-Nph-5′-TMP to its allosteric binding
site, which may be close or even distant from the active site,
could induce a conformational change of the substrate binding
site. This would modulate the interaction of competitive
inhibitors with the substrate binding site, and could therefore
explain the increased affinity of the investigated competitive
inhibitors (Figure 9). This hypothesis is supported by the
fact that the affinity increase depends on the structure of the
inhibitors, e.g. some competitive inhibitors (e.g., 15) being
much more strongly affected than others (see also Table 1 and
Figure 9).
This hypothesis also provides a straightforward explanation
for the finding that p-Nph-5′-TMP is a much better NPP1
substrate than p-Nph-5′-AMP despite the fact that—based on
docking studies—the AMP derivative should have stronger
interactions with the substrate binding site. p-Nph-5′-TMP may
FIGURE 8 | Correlation analyses between the results (A) for
competitive inhibitors, and for (B) non- and un-competitive inhibitors
obtained with different substrates. Determined correlation coefficients (R2)
were calculated by fitting pKi-values obtained with one substrate vs. those
obtained with another substrate using the software Prism 5.0; red points, test
compounds; solid line, the best fit line of the linear regression; the dotted line
in (A) represents the ideal correlation (R2 = 1.00).
additionally bind to an allosteric site and thereby act as a positive
allosteric modulator which increases its binding affinity to the
substrate binding site and accelerates its hydrolysis.
Further, investigations to corroborate this hypothesis of
allosteric modulation of the active site by p-Nph-5′-TMP are
warranted.
CONCLUSIONS
In conclusion, we observed substrate-dependence of the
inhibitory potency of NPP1 inhibitors, competitive inhibitors
being (much) more potent vs. the artificial substrate p-Nph-
5′-TMP than vs. the natural nucleotide substrate ATP. In
contrast, data obtained using the new artificial substrate p-Nph-
5′-AMP correlated well with those determined vs. the natural
substrate ATP indicating that the nucleoside part of the artificial
substrate was responsible for the observed effects. No significant
differences in inhibitory potencies were observed for non- or
un-competitive inhibitors. The most likely explanation for the
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FIGURE 9 | Possible explanation for the discrepancies observed for competitive inhibitors vs. the artificial substrate p-Nph-5′-TMP (higher affinity
observed for competitive antagonists) as compared to natural substrates assays (lower affinity for competitive inhibitors). p-Nph-5′-TMP may not only
act as a substrate, but also as an allosteric modulator.
observed phenomenon is an allosteric modulation of NPP1 by
the artificial substrate p-Nph-5′-TMP, but not by p-Nph-5′-AMP.
Therefore, we recommend to use p-Nph-5′-AMP instead of
p-Nph-5′-TMP for high-throughput screening of NPP1 using
colorimetric detection. Further, investigations to explain the
discrepancy between results with the commonly used artificial
substrate p-Nph-5′-TMP and the natural substrate ATP are in
progress.
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